Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adenocarcinoma
Research from University of Heidelberg in adenocarcinoma provides new insights
February 3rd, 2009
"Alpha-fetoprotein-producing metastatic adenocarcinoma of the stomach or the esophago-gastric junction usually exhibits either no or only short-term remission while receiving palliative chemotherapy," scientists writing in the journal Anti - Cancer Drugs report. "We report on a 76-year-old male patient suffering from an unresectable alpha-fetoprotein-producing adenocarcinoma of the esophago-gastric junction with several liver metastases. He was treated with capecitabine and oxaliplatin-based combination therapy," wrote M. Kripp and colleagues, University of Heidelberg. The researchers concluded: "A long-lasting major remission was observed...
Source: Cancer Weekly (2009-02-03)
|
